A5029391117- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Synthesis and biological activity
- Synthesis and Characterization of Heterocyclic Compounds
- Sirtuins and Resveratrol in Medicine
- Enzyme function and inhibition
- Prostate Cancer Treatment and Research
- Computational Drug Discovery Methods
- Adenosine and Purinergic Signaling
- Molecular Biology Techniques and Applications
- Phytochemicals and Antioxidant Activities
- Nanoplatforms for cancer theranostics
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Virus-based gene therapy research
- Melanoma and MAPK Pathways
- Apelin-related biomedical research
- Immune Response and Inflammation
- PI3K/AKT/mTOR signaling in cancer
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Histone Deacetylase Inhibitors Research
- interferon and immune responses
Dana-Farber Cancer Institute
2021-2023
Center for Orthopaedics
2023
Baylor College of Medicine
2022-2023
Harvard University
2022
Children's Cancer Center
2022
Long Island University
2017-2019
Abstract Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, isoforms highly heterogeneous, and data on potential isoform-dependent therapeutic vulnerabilities still lacking. Experimental Design: We developed an isogenic cell-based platform to compare properties specific actionability KRAS-mutant isoforms. In parallel, we analyzed clinicopathologic genomic from 3,560 patients with non–small cell cancer (NSCLC)...
MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non-small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we assess secondary mutations likely to emerge response treatment with single-agent...
ABSTRACT Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, with overall long-term survival rates of ∼65-70%. Thus, additional molecular insights and representative models are critical for identifying evaluating new treatment modalities. Using MyoD-Cre-mediated introduction mutant K-RasG12D perturbations p53, we developed a novel genetically engineered mouse model (GEMM) RMS. The anatomic sites primary RMS development recapitulated human disease, including tumors...
Tumor progression and resistance to therapy in children with neuroblastoma (NB), a common childhood cancer, are often associated infiltration of monocytes macrophages that produce inflammatory cytokines. However, the mechanism by which tumor-supportive inflammation is initiated propagated remains unknown. Here, we describe novel protumorigenic circuit between NB cells triggered sustained tumor necrosis factor alpha (TNF-α). We used knockouts (KOs) TNF-α TNFRSF1A mRNA (TNFR1)/TNFRSF1B (TNFR2)...
Abstract Metastasis-associated protein 1 is known to play role in prostate cancer progression and metastasis. Studies of MTA1-mediated tumorigenesis, metastasis have been hampered by a lack suitable experimental system. Here we describe new conditional mouse model that shows strong MTA1 expression the prostate. This was generated through transgene knocked into ROSA26 (R26) locus using CAG-LoxP-Stop-LoxP (LSL)-2HA-MTA1-T2A-GFP-pA construct (Applied StemCell,Inc, Menlo Park, CA). Briefly,...
The overexpression of metastasis-associated protein 1 (MTA1) in prostate cancer (PCa) contributes to tumor aggressiveness and metastasis. We have reported the inhibition MTA1 by resveratrol its potent analog pterostilbene vitro vivo. demonstrated that treatment blocks progression prostatic intraepithelial neoplasia adenocarcinoma mouse models inhibiting expression signaling. In current study, we investigated targeted anticancer effects Gnetin C, a dimer, comparison with pterostilbene. Using...
Although the link between diet and cancer is complex, epidemiological data confirm that a risk factor for prostate indicate reduced incidence associated with rich in vegetables fruits. Because of known protective effect grape seed extract (GSE) against cancer, we evaluated effects powder (GPE) on cell viability, proliferation, metastatic capability. Importantly, explored possible novel mechanism GPE through metastasis-associated protein 1 (MTA1) downregulation since our previous studies...
A subset of drug-resistant EGFR -mutant MET -amplified lung cancer switches oncogenic dependence to and is treatable with inhibitor monotherapy.
Animal models of asthma have shown that limonene, a naturally occurring terpene in citrus fruits, may beneficial effects by reducing inflammation and airway reactivity. However, the mechanism these is unknown. We hypothesized limonene activates A2A adenosine receptors (A2AAR) to produce its asthma. Computational analysis comparing Glide scores for Limonene (-5.19) A2AAR agonist CGS 21680 (-8.43) suggests binds as an agonist. then investigated pharmacological on lung responsiveness...
Abstract Overexpression of chromatin modifier protein, metastasis-associated protein 1 (MTA1) in prostate cancer contributes to tumor aggressiveness and metastasis. MTA1 ChiP-Seq analysis identified downstream targets that are transcriptionally regulated by suggested a link between ETS2. The effects ETS2 context-dependent both oncogenic suppressive functions have been described. We shown there is positive correlation using loss function studies various preclinical models cancer. Our...
There is evidence that inflammatory exacerbations in asthma may be mediated by specific endogenous peptides. Apelin, an hypotensive and angiogenic peptide, increased atopic asthma. However, it unclear how apelin affects allergic inflammation observed We studied the role of exogenously administered airway hyperreactivity mice. Mice were divided into control (CON) allergen sensitized‐challenged (SEN) groups. sensitized (i.p.) on days 1, 6 with 0.2μg ovalbumin (OVA) followed 5% OVA aerosol...
<div>AbstractPurpose:<p>Activating missense mutations of <i>KRAS</i> are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms highly heterogeneous, and data on potential isoform-dependent therapeutic vulnerabilities still lacking.</p>Experimental Design:<p>We developed an isogenic cell-based platform to compare properties specific actionability KRAS-mutant isoforms. In parallel, we analyzed clinicopathologic...
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
<div>AbstractPurpose:<p>Activating missense mutations of <i>KRAS</i> are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms highly heterogeneous, and data on potential isoform-dependent therapeutic vulnerabilities still lacking.</p>Experimental Design:<p>We developed an isogenic cell-based platform to compare properties specific actionability KRAS-mutant isoforms. In parallel, we analyzed clinicopathologic...
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer
<p>Application of Bliss independence to test for synergy effect TKI combination treatment in vivo</p>
<p>Supplementary Figures S1-3; Supplementary Tables S1-3</p>
<div>Abstract<p>MET-targeted therapies are clinically effective in <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant (<i>MET</i>ex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we...
<div>Abstract<p>MET-targeted therapies are clinically effective in <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant (<i>MET</i>ex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we...
<p>Supplementary Figures S1-3; Supplementary Tables S1-3</p>
<p>Application of Bliss independence to test for synergy effect TKI combination treatment in vivo</p>